Olympus (OCPNY) vs. Its Rivals Head to Head Contrast
by Jessica Moore · The Cerbat GemOlympus (OTCMKTS:OCPNY – Get Free Report) is one of 515 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Olympus to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends.
Institutional & Insider Ownership
0.0% of Olympus shares are owned by institutional investors. Comparatively, 40.1% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Olympus and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olympus | 13.80% | 24.30% | 9.30% |
| Olympus Competitors | -275.79% | -158.03% | -22.38% |
Earnings & Valuation
This table compares Olympus and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Olympus | $7.74 billion | $1.03 billion | 21.95 |
| Olympus Competitors | $1.88 billion | $144.09 million | 8.31 |
Olympus has higher revenue and earnings than its peers. Olympus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Dividends
Olympus pays an annual dividend of $0.08 per share and has a dividend yield of 0.4%. Olympus pays out 9.8% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.4% and pay out 44.6% of their earnings in the form of a dividend.
Risk and Volatility
Olympus has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Olympus’ peers have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Olympus and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
| Olympus Competitors | 4205 | 10291 | 17924 | 794 | 2.46 |
As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 32.34%. Given Olympus’ peers higher possible upside, analysts plainly believe Olympus has less favorable growth aspects than its peers.
Summary
Olympus beats its peers on 9 of the 15 factors compared.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.